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Evaluation and 
Validation of a Real-
Time Polymerase 
Chain Reaction 
Assay for Rapid 
Identification of 
Bacillus anthracis
To the Editor: During the 2001
anthrax outbreak, we evaluated and
validated a highly sensitive and spe-
cific three-target (two plasmid and one
chromosomally located target) 5´
nuclease assay (real-time polymerase
chain reaction [PCR]) for detection
and identification of Bacillus anthra-
cis. This PCR assay was successfully
used to rapidly test hundreds of sus-
pect isolates as well as screen environ-
mental samples for the presence of B.
anthracis throughout the 2001 anthrax
outbreak. For the first time in an out-
break setting, a PCR assay was used to
detect B. anthracis directly from clini-
cal specimens, consequently becom-
ing a part of the laboratory
confirmation of anthrax. In this letter,
we describe the evaluation of this
assay on a diverse panel of bacterial
isolates including isolates obtained
throughout the outbreak. A supple-
ment, which includes data on the use
of this assay on environmental and
clinical specimens, is online (available
from: URL: http://www.cdc.gov/ncid/
EID/vol8no10/02-0393_sup.htm).
Identification of B. anthracis has
traditionally been determined by using
phenotypic differences between B.
anthracis and the rest of the B. cereus
group (i.e., lack of motility and hemol-
ysis, susceptibility to penicillin, typi-
cal colony morphology, and
susceptibility to lysis by gamma
phage); however, these methods are
slow and require at least 24 h for com-
pletion. The recent bioterrorism-asso-
ciated outbreak and the ongoing threat
emphasize the importance of rapid
microbiologic diagnosis for the timely
and adequate implementation of con-
trol and preventative measures.
For B. anthracis, the main targets
for development of such assays, pri-
marily PCR-based, have been and
continue to be genes encoding its viru-
lence factors: a tripartite exotoxin and
an antiphagocytic capsule (1–4). The
toxin genes (pagA, lef, and cya) are
encoded on the 182-kb virulence plas-
mid, pXO1, while the genes required
for capsule biosynthesis (capB, capC,
and capA) are encoded on the 96-kb
virulence plasmid, pXO2 (5–7). These
plasmid-located virulence genes seem
to be restricted to B. anthracis, giving
the plasmid-based assays a high
degree of specificity (8). However,
strains of B. anthracis that lack these
plasmids have been reported (4,9).
Consequently, having an assay focus
on a specific chromosomal target for
detection of avirulent and plasmid-
cured  B. anthracis, as well as those
that potentially could have been genet-
ically engineered, is essential. Chro-
mosomal markers, such as vrrA and
Ba813, have been used to characterize
B. anthracis (9–12) and to detect it in
tissues of victims of the anthrax out-
break that occurred in 1979 in Sverd-
lovsk, former Soviet Union (12), but
these markers are not restricted to B.
anthracis. Recently, Qi et al. devel-
oped a fluorescence resonance energy
transfer PCR assay that targets the B.
anthracis  chromosomally located
rpoB gene. This assay appears to be
the most specific described to date
with only 1 of 175 non-B. anthracis
bacilli reported as positive (13). 
Over the past several years, activi-
ties in the area of bioterrorism pre-
paredness in the United States have
resulted in the establishment of an
international Laboratory Response
Network (LRN), which was instru-
mental in the identification of the
agent used in the 2001 outbreak (14).
One of the major initiatives of LRN
has been development and validation
of rapid and specific assays for identi-
fication of B. anthracis and other
agents likely to be used in a bioterror-
ism event.
Primer and probe set BA1 targets a
region of pX02, BA2 targets pXO1,
and BA3 targets a region of the B.
anthracis chromosome. Probes were
labeled with 6-carboxy-fluorescein
phosphoramidite and 5-carboxy-tet-
ramethyl-rhodamine.
LRN PCR assays using the BA1,
BA2, and BA3 primer and probe sets
were performed with the LightCycler
(Roche Diagnostics GmbH, Man-
nheim, Germany), Smart Cycler (Cep-
heid, Sunnyvale, CA), or ABI Prism
7700 (Applied Biosystems, Foster
City, CA) instruments. The LightCy-
cler Faststart DNA master hybridiza-
tion probes kit (Roche Diagnostics
GmbH) reagents were used on all real-
time platforms. Reactions comprised
1X reaction mix, 5 mM MgCl2, 500
nM each primer, and 100 nM probe in
a reaction volume of 20 µL (LightCy-
cler) or 25 µL (Smart Cycler, ABI
Prism 7700). Thermal cycler condi-
tions consisted of an initial 10-min
hold at 95°C followed by 40–45
cycles of 10 s (LightCycler) or 15 s
(Smart Cycler, ABI Prism 7700) at
95°C and 30 s (LightCycler, Smart
Cycler) or 60 s (ABI Prism 7700) at
60°C. Real-time data were collected
during the 60°C extension step of each
cycle. Amplification of the human β -
actin gene was used as a real-time
PCR control when used in clinical
samples to ensure negative results
were not from inhibition of the PCR
reaction. This real-time PCR assay
was considered positive when all three
targets were positive (Figure).
A total of 542 isolates were tested.
Eighty-one B. anthracis isolates were
tested to evaluate sensitivity of the
real-time PCR approach (Table). Sev-
enty-five were selected to provide a
test population representing diverse
sources, genotypes, geographic ori-
gins, and dates of isolation. The iso-
lates included those collected from
animals, humans, and other sources
(i.e., industrial sites associated with
anthrax outbreaks); the isolates span at
least 58 years (1939–1997). Fifty-
three of the isolates were previously
characterized by multiple-locus vari-
able-number tandem repeat analysis
(MLVA) (15) and were included to
ensure a representative range of the 89
described MLVA genotypes to date.Emerging Infectious Diseases  •  Vol. 8, No. 10, October 2002 1179
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Six  B. anthracis type and standard
strains included: five pXO1 cured
strains (including the Pasteur strain)
and one pXO2 cured strain (the veteri-
nary vaccine strain Sterne). The B.
anthracis New Hampshire strain (16)
was used as a positive control for all
real-time PCR assays. This isolate was
originally cultured from a patient with
inhalational anthrax in New Hamp-
shire in 1957. This real-time PCR is
designed to identify fully virulent
(wild-type)  B. anthracis, which will
give positive results in all three mark-
ers. However, naturally occurring iso-
lates have been found lacking either
virulence plasmid, and a number of
laboratory strains have been plasmid
cured, as well. PCR results for these
strains will reflect the lack of one or
both of their plasmids. 
A total of 317 B. anthracis isolates
obtained during the bioterrorism-asso-
ciated anthrax outbreak from October
to December 2001 were also analyzed
by PCR. These included 27 isolates
from clinical specimens, 4 from pow-
ders and 286 isolates from environ-
mental samples. MLVA was
performed on 135 of these isolates; all
were indistinguishable (17).
For evaluation of the assays’ spec-
ificity we tested 56 archived members
of the Bacillus genus: B. subtilis (9
strains, 5 clinical, 4 unknown), B.
cereus (23 strains, 9 clinical, 14 envi-
ronmental), B. thuringiensis (12
strains, 6 clinical, 3 insects, 3
unknown), B. mycoides (1 strain,
unknown), B. megaterium (10 strains,
7 clinical, 3 unknown), and the envi-
ronmental  Bacillus spp. isolate,
Ba813_11, which resulted in a previ-
ously reported false-positive result in
the  B. anthracis-specific PCR assay
targeting  rpoB  (13). In addition, 88
isolates from environmental and clini-
cal specimens, which were confirmed
not to be B. anthracis by standard
microbiologic methods were tested.
These isolates were selected because
of their lack of hemolysis and because
they had a colony morphology similar
to B. anthracis on blood agar plates.
Before testing, all strains were
stored at –70°C in brain heart infusion
broth (BHIB, Centers for Disease
Control and Prevention [CDC],
Atlanta, GA) or water containing 20%
glycerol. Identification of all strains
was confirmed by using standard
microbiologic procedures and the
LRN testing algorithm (14,18). Col-
ony-lysis DNA preparations were
used for all Bacillus spp. strains. Iso-
lates were streaked onto trypticase soy
agar containing 5% sheep blood (Bec-
ton Dickinson Microbiology Systems,
Cockeysville, MD) and incubated
overnight at 37°C. A single colony
was transferred and dispersed into
0.22 µM centrifugal filter units (Milli-
pore, Bedford, MA)  containing 200
µL 10 mM Tris-HCl (pH 8.0). The
suspension was heated at 95°C for 20
min and then cooled to room tempera-
ture. The filter units were then centri-
fuged at 6,000 x g in a microfuge for 2
min and the filter discarded. The
resulting lysate was stored at –20°C
until use. 
The lower limit of detection of
each assay was tested by using five B.
anthracis strains: Ames (2000
031656), Pakistan-sheep (20000316
48),  French-bovine (2000031651),
Sterne (2000031075), and Pasteur (20
00031759). DNA was extracted from
vegetative cells by first pre-treating
cell pellets with lysozyme and lysos-
taphin and then using the MasterPure
DNA Purification kit (Epicentre, Mad-
ison, WI), following the manufac-
turer’s protocol for cell samples. B.
anthracis spores were quantitated
microscopically and tested directly in
the real-time PCR assay without DNA
extraction. Vegetative-cell DNA was
tested at concentrations ranging from
10 ng to 400 fg DNA per reaction.
Spores were tested at concentrations
ranging from 100,000 spores to 1
spore per reaction. All reactions were
performed in duplicate on the Light-
Cycler, Smart Cycler, and ABI Prism
7700 instruments. 
All 75 wild-type (fully virulent) B.
anthracis isolates tested were positive
for all three targets resulting in 100%
sensitivity (95% confidence interval
[CI] 95% to 100%). Strains cured of
pXO1 or pXO2 produced negative
results for the loci specific to these
plasmids (Table). In addition, all 317
B. anthracis isolates from the 2001
outbreak were also positive for all
three PCR targets (Table). 
None of the 56 archived non–B.
anthracis  isolates, representing five
other Bacillus species was positive for
any of the three LRN PCR targets,
Figure. Real-time polymerase chain reaction graph of three Bacillus anthracis markers and β -
actin control detected in a pleural fluid specimen from a patient with inhalational anthrax. The
horizontal line indicates a threshold value; the vertical lines indicate cross-threshold values for
each marker. BA1, primer and probe set targeting a region of pXO2; BA2, primer and probe set
targeting a region of pXO1; BA3, primer/probe set targeting a region of B. anthracis chromo-
some.LETTERS
1180 Emerging Infectious Diseases  •  Vol. 8, No. 10, October 2002
including the Bacillus spp. isolate,
Ba813_11, resulting in 100% specific-
ity (95% CI 94% to 100%). Results
were also negative for 88 clinical and
environmental isolates, which were
determined by standard microbiologic
methods not to be B. anthracis (speci-
ficity 100%, 95% CI 96% to 100%).
The limit of detection on the
LightCycler, Smart Cycler, and ABI
Prism 7700 instruments, as deter-
mined by using DNA extracted from
vegetative cells of the Sterne and Pas-
teur reference strains, was 1 pg DNA
(approximately 167 cells based on a
5.5 Mbp genome size). Five to 10
spores could be detected on the ABI
Prism 7700 instrument for the Ames
(2000031656), Pakistan-sheep (20000
31648), French-bovine (2000031651),
and Sterne (2000031075) strains of B.
anthracis.
The recent bioterrorism-associ-
ated anthrax outbreak demonstrated
the need for sensitive, specific, and
rapid methods for diagnosis and con-
firmation of anthrax, both for identifi-
cation of suspect B. anthracis isolates
and direct detection of B. anthracis
DNA in clinical specimens. When
tested on >500 strains, representing B.
anthracis and five other Bacillus spe-
cies, the LRN PCR exhibited 100%
sensitivity and specificity. 
To date, designing PCR assays for
identification of B. anthracis has pri-
marily focused on genes located on
the plasmids (1–4). Patra et al. used a
PCR that targeted two chromosomal
loci,  vrrA and Ba813, and found
numerous environmental Bacillus iso-
lates other than B. anthracis that were
positive for both Ba813 and vrrA (11).
While assays focusing on plasmid tar-
gets allow for a high level of specific-
ity, a specific chromosomal target for
detection of avirulent and plasmid-
cured B. anthracis strains is needed.
Thus, the LRN PCR includes a chro-
mosomal target in addition to targets
on each of the two virulence plasmids,
pXO1 and pXO2.
Closely related  B. cereus and B.
thuringiensis, notorious for generating
false-positive results using assays
designed to be specific for B. anthra-
cis (11,13), were consistently negative
in this real-time PCR assay. B. anthra-
cis, B. cereus, and B. thuringiensis are
so closely related that their distinction
as separate species is frequently ques-
tioned based on DNA-DNA hybrid-
ization studies, multiple-locus enzyme
electrophoresis, and 16S rRNA
sequence similarity (19–21). We have
selected non–B. anthracis isolates that
were primarily of clinical as opposed
to environmental origin. B. cereus and
B. thuringiensis clinical isolates are
even more closely related to B.
anthracis than their environmental
counterparts (19,22), and they are
more likely to cause false-positive
results. We also tested the Bacillus
spp. isolate that caused the one false-
positive result in the Qi et al. report
(13). Despite all of these challenges,
all three targets of this real-time PCR
assay have demonstrated 100% speci-
ficity and sensitivity in identification
of B. anthracis when tested against
our panel of Bacillus spp. strains and
in identification of 317 outbreak-asso-
ciated B. anthracis isolates. This LRN
PCR is currently the only real-time
PCR assay that detects both plasmid
and chromosomal targets with 100%
specificity and sensitivity. In addition,
real-time PCR assays using fluores-
cent probes provide great sensitivity;
this assay was able to detect 1 pg of
purified DNA from vegetative cells
(equivalent to 167 cells) or directly
detect 5–10 spores.
The high level of sensitivity and
specificity of the LRN PCR assay can
be attributed to several factors. An
extensive panel of DNA samples
(non-Bacillus gram-positive bacterial
species, gram-negative bacterial spe-
cies, and human, vertebrate, and inver-
tebrate DNA) were tested (data not
shown). Having more than a single
target decreases the rate of both false-
negative and false-positive results, as
they are not dependent on a single
locus. The use of multiple targets also
decreases the risk of false-positive
results from contamination because
each target is amplified as a separate
PCR reaction. Finally, 5´ nuclease
Table.  Origin, designations, and results of real-time polymerase chain reaction assay for Bacillus anthracis strains
B. anthracis No. analyzed Temporal range and geographic origin MLVA genotypes representeda
No. positive/total
Ba1b Ba2b Ba3b
Human isolates 30 1943–1996 
Africa, Asia, Australia, Europe, North America
3, 4, 22, 23, 28, 32, 34, 35, 36, 37, 
41, 43, 44, 45, 50, 66, 68
30/30 30/30 30/30
Animal isolates 29 1939–1997
Africa, Asia, Australia, Europe, 
North America, South America
3, 10, 20, 26, 29, 30, 35, 38, 40, 
45, 48, 49, 51, 55, 57, 78, 80, 
81, 84, 85, 87, 89
29/29 29/29 29/29
Other isolates 16 1950–1993
Africa, Asia, Europe, N. America
13, 14, 21, 24, 47, 62, 69, 73, 
77, 79, 82
16/16 16/16 16/16
Outbreak isolates 317 2001
U.S. outbreak
62 317/317 317/317 317/317
pXO1 cured 5 1956–1974
 North America
5/5 0/5 5/5
pXO2 cured 1 Africa 0/1 1/1 1/1
aMLVA, multiple-locus variable-number tandem repeat analysis as described by Keim et al. (15).
bBa1, Ba2, and Ba3 primer/probe sets as described in Materials and Methods.Emerging Infectious Diseases  •  Vol. 8, No. 10, October 2002 1181
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assays makes use of a fluorescent oli-
gonucleotide probe, in addition to the
forward and reverse primers, that
allows for a lower limit of detection
compared to conventional PCR, elimi-
nates the need for post-PCR process-
ing, and increases specificity (23,24).
The LRN PCR was shown to be
important for use on environmental
and clinical specimens during the
2001 bioterrorism-associated anthrax
outbreak. A supplement covering the
use of this assay on these specimens
can be seen online (available from:
URL: http://www.cdc.gov/ncid/EID/
vol8no10/02-0393_sup.htm). The
LRN PCR assay is widely available at
over 200 laboratories in several coun-
tries and all 50 states of the United
States through the Laboratory
Response Network. The system is
designed to be accessed through the
State Department of Health. 
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Industry-Related 
Outbreak of 
Human Anthrax, 
Massachusetts, 
1868
To the Editor: In Bioterrorism-
Related Inhalational Anthrax: The
First 10 Cases Reported in the United
States, Jernigan et al. noted that in the
mid-1800s inhalational anthrax related
to the textile industry became known
as woolsorters’ disease (in England)
and ragpickers’ disease (in Germany
and Austria) because of the frequency
of infection in mill workers exposed to
imported animal fibers contaminated
with  Bacillus anthracis spores (1).
During the 1800s, as in Europe, indus-
try-related human cases of anthrax
also occurred in the United States.
In 1868, Silas Stone, a physician,
reported that “an unusual number of
cases of a rather rare affection have
come under my observation within the
past 14 months” (2). Stone described
eight patients with “malignant pus-
tules” who worked in or were associ-
ated with an animal hair factory in
Massachusetts. The patients’ cutane-
ous lesions were described as dark red,
dark purple, purplish-black, and black;
six of the patients had “slough”
lesions. Stone treated his patients with
tincture of iodine, iron, and quinine.
Since antibiotics were not available,
six of the eight patients had severe
clinical disease, and two died. Stone’s
patients demonstrated the full spec-
trum of anthrax, including gastrointes-
tinal, mediastinal, and meningeal
involvement. Four patients had gas-
trointestinal symptoms, including epi-
gastric distress and pain, nausea, and
vomiting. Three patients had mediasti-
nal involvement, manifested by chest
distress and pain, dyspnea, and tac-
hypnea. In the two fatal cases, menin-
gitis appeared to have been the
immediate cause of death; both of
these patients were described as
delirious.
Among Stone’s eight patients,
most remarkable was case 5, which
was strikingly similar to case 8 of
Jernigan et al.; the signs and symp-
toms of both patients included chills,
headache, fatigue, vomiting, chest
pain, tachypnea, tachycardia, and
cutaneous lesions. Stone’s description
of the 7-day clinical course of patient
5, a laborer at the hair factory, is as
follows: “Called November 17. Had
been sick since the Thursday previous
(November 14). Was taken with chills,
pain in head and back, and suffered
loss of strength. When first seen, was
in bed . . . had not slept well the previ-
ous night. Pain and distress in epigas-
trium and back. Pulse 120 . . .
breathing hurried. Discovered a dark
purple spot surrounded by yellow ves-
icles . . . pressure on slough produced
no pain. November 18: Slough dou-
bled in size. November 19: Vomited . .
. severe chill. November 20: Sleep
restless . . . slough one inch by half an
inch, much raised above surrounding
skin, with a red areola about an inch in
width. November 21: a.m.: Delirious
part of night . . . slept but little . . . pain
in chest. 3 p.m.: Distress at epigas-
trium great . . . delirium more violent.
8 p.m.: Distress and delirium greater .
. . pulse failing . . . sinking rapidly . . .
died soon after visit.” 
Stone perceptively noted that each
of his patients was directly or indi-
rectly exposed to hair or dirt from the
animal hair factory, and that in the sur-
rounding population not so exposed,
no cases were seen. Stone realized that
he was dealing with an industry-
related disease and hypothesized that
the cause was “a specific poison, and
not simply putrescent animal matter.”
Nine years after Stone’s 1868 report,
Robert Koch in Germany reported iso-
lation and cultivation of B. anthracis,
the formation of its spores, the produc-
tion of anthrax disease with pure cul-
tures, and the recovery of B. anthracis
from experimental infection (3).
 Abe Macher
Health Resources and Services Administra-
tion, U.S. Public Health Service, Rockville,
Maryland, USA
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